High replicative full-length lamivudine-resistant hepatitis B virus isolated during acute exacerbations

Journal of Medical Virology

Volumn 77, Issue 2, 2005, Pages 203-208

  Zhang, Ji Ming ^a,b   Yao, Xin ^a   Wang, Yong Xiang ^a   Liu, Fang ^a   Ma, Zhang Mei ^a   Weng, Xing Hua ^b   Wen, Yu Mei ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Hepatitis B virus; Liver disease; Replication

Indexed keywords

LAMIVUDINE;

ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; GENE AMPLIFICATION; GENETIC ANALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN MOTIF; STRAIN DIFFERENCE; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS RESISTANCE;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; FEMALE; GENE EXPRESSION; GENES, VIRAL; GENOME, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MUTATION; VIRAL LOAD; VIRUS REPLICATION;

HEPATITIS B VIRUS; LETTUCE MOSAIC VIRUS;

EID: 24644525028     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20453     Document Type: Article

References (31)

1. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677.
2. Ayres A, Bartholomeusz A, Lau G, Lam KC, Lee JY, Locarnini S. 2003. Lamivudine and famciclovir resistant hepatitis B virus associated with fatal hepatic failure. J Clin Virol 27:111-116.
3. Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP, Trautwein C. 2002. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 122:264-273.
4. Brown JL, Carman WF, Thomas HC. 1992. The clinical significance of molecular variation within the hepatitis B virus genome. Hepatology 15:144-148.
5. Cacciola I, Cerenzia G, Pollicino T, Squadrito G, Castellaneta S, Zanetti AR, Mieli-Vergani G, Raimondo G. 2002. Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection. J Hepatol 36:426-432.
6. Chisari FV. 1997. Cytotoxic T cells and viral hepatitis. J Clin Invest 99:1472-1477.
7. Chu CJ, Lok ASF. 2002. Clinical significance of hepatitis B virus genotypes. Hepatology 35:1274-1276.
8. Delaney WE 4th, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD, Xiong S. 2003. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 77:11833-11841.
9. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256-1263.
10. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. 2003. Histological outcome during long-term lamivudine therapy. Gastroenterology 124:105-117.
11. Doo E, Liang TJ. 2001. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 120:1000-1008.
12. Ehata T, Omata M, Chuang WL, Yokosuka O, Ito Y, Hosoda K, Ohto M. 1993. Mutations in core nucleotide sequence of hepatitis B virus correlate with fulminant and severe hepatitis. J Clin Invest 91:1206-1213.
13. Fischer KP, Gutfreund KS, Tyrrell DL. 2001. Lamivudine resistance in hepatitis B: Mechanisms and clinical implications. Drug Resist Updat 4:118-128.
14. Guidotti LG, Chisari FV. 1996. To kill or to cure: Options in host defense against viral infection. Curr Opin Immunol 8:478-483.
15. Gunther S, Li BC, Miska S, Kruger DH, Meisel H, Will H. 1995. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 69:5437-5444.
16. Hadzyiannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. 2000. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32:847-851.
17. Khan N, Guarnieri M, Ahn SH, Li J, Zhou Y, Bang G, Kim KH, Wands JR, Tong S. 2004. Modulation of hepatitis B virus secretion by naturally occurring mutations in the S gene. J Virol 78:3262-3270.
18. Lau DTY, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH. 2000. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32:828-834.
19. Leung NWY, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RM. 2001. Extended lamivudine treatment in patients with chronic hepatitis Benhances hepatitisBe antigen seroconversion rates: Results after 3 years of therapy. Hepatology 33:1527-1532.
20. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. 1999. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30:567-572.
21. Liaw YF, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. 2000. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119:172-180.
22. Lin X, Yuan ZH, Wu L, Ding JP, Wen YM. 2001. A single amino acid in the reverse transcriptase domain of hepatitis B virus affects virus replication efficiency. J Virol 75:11827-11833.
23. Lindh M, Gustavson C, Mardberg K, Norkrans G, Dhillon AP, Horal P. 1998. Mutation of nucleotide 1762 in the core promoter region during hepatitis B e seroconversion and its relation to liver damage in hepatitis B e antigen carriers. J Med Virol 55:185-190.
24. Liu CJ, Chen PJ, Lai MY, Kao JH, Chen DS. 2001. Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. Hepatology 34:583-589.
25. Melegari M, Scaglioni PP, Wands JR. 1997. The small envelope protein is required for secretion of a naturally occurring hepatitis B virus mutant with pre-S1 deleted. J Virol 71:5449-5454.
26. Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, Omata M. 1999. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitrofull-length viral DNA transfection. Hepatology 29:939-945.
27. Rehermann B, Fowler P, Sidney J, Chisari FV. 1995. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 181:1047-1058.
28. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. 2001. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33:751-757.
29. Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. 2004. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants. J Virol 78:8524-8535.
30. Yuh CH, Chang YL, Ting LP. 1992. Transcriptional regulation of precore and pregenomic RNAs of hepatitis B virus. J Virol 66:4073-4084.
31. Zoulim F. 2002. Assessing hepatitis B virus resistance in vitro and molecular mechanisms of nucleoside resistance. Semin Liver Dis 22:23-31.